Amicoat develops and commercializes groundbreaking antimicrobial technology based on nature's own defense mechanisms. Our focus is on antimicrobial agents that inhibit bacterial growth and the formation of biofilms. We offer a highly promising solution to the growing global antibiotic resistance epidemic. Our peptides, when in contact with bacteria, induce rapid bactericidal activity and nearly instantaneous bacterial cell death, before mechanisms of resistance can be conferred.
Read moreTough on bacteria. Benign on environment.
Our main product, AMC-109, induces rapid bacterial cell death by disrupting the structural integrity of the bacterial cell membrane, resulting in cell lysis. Due to the rapid mechanism of action, bacteria do not have the opportunity to acquire resistance through conjugation or transformation. Our product is backed by extensive efficacy and safety data. Efficacy has also been demonstrated with viruses and fungi.
Amicoat AS is a privately owned biotechnology company with offices in Oslo and Tromsø, Norway. Our aspiration is to be the market leader in the antimicrobial space. Many factors make Amicoat a compelling business case: proprietary patented technology, leading scientific experts, a highly competent management team, and a growing market demand for our solutions. We welcome discussions with investors.
Read moreAt Amicoat, you will have the opportunity to work at the forefront of biotechnology. Amicoat's technology addresses critical problems related to bacterial growth affecting human health and welfare. Our company is committed to recruiting and hiring individuals who share our passion for science and our desire to build a great company.
View Job openingsWe tested the contact form and were unable to receive the message, could you please route message to contact@amicoat.com